Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4.31%6.63B | 8.36%27.88B | 5.69%6.36B | 7.79%25.73B | 4.76%7.22B | 3.68%6.41B | 8.43%6.09B | 16.01%6.01B | 5.44%23.87B | 5.80%6.89B |
| Cost of revenue | 9.98%3.34B | 8.95%13.82B | 9.89%3.04B | 4.23%12.68B | 4.99%3.74B | 4.70%3.18B | 3.55%2.99B | 3.42%2.76B | 8.07%12.17B | 4.20%3.56B |
| Gross profit | -0.87%3.29B | 7.79%14.06B | 2.11%3.32B | 11.48%13.05B | 4.51%3.48B | 2.69%3.22B | 13.61%3.1B | 29.41%3.25B | 2.85%11.7B | 7.57%3.33B |
| Operating expense | -6.37%2.46B | 4.78%10.03B | 13.41%2.63B | 8.05%9.57B | 8.07%2.63B | 2.23%2.29B | 11.17%2.33B | 11.15%2.32B | 7.07%8.86B | 12.55%2.43B |
| Staff costs | ---- | 1.59%5.23B | ---- | 10.23%5.15B | ---- | ---- | ---- | ---- | 5.00%4.67B | ---- |
| Research and development costs | ---- | -11.98%782.65M | ---- | 0.14%889.17M | ---- | ---- | ---- | ---- | -4.20%887.94M | ---- |
| Depreciation and amortization | ---- | 5.94%68.46M | ---- | 131.71%64.63M | ---- | ---- | ---- | ---- | 173.02%27.89M | ---- |
| -Depreciation | ---- | --0 | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| -Amortization | ---- | 5.94%68.46M | ---- | 131.71%64.63M | ---- | ---- | ---- | ---- | 173.02%27.89M | ---- |
| Other operating expenses | ---- | 13.79%3.95B | ---- | 6.04%3.47B | ---- | ---- | ---- | ---- | 13.28%3.27B | ---- |
| Operating profit | 20.03%829.65M | 16.09%4.03B | -25.94%691.21M | 22.17%3.47B | -5.16%848.65M | 3.83%931.56M | 21.81%761.42M | 118.50%933.27M | -8.40%2.84B | -3.99%894.86M |
| Net non-operating interest income (expenses) | -189.82%-247K | 28.52%11.06M | -40.86%275K | 195.40%8.6M | 354.21%5.45M | 92.23%1.14M | 205.11%1.55M | -24.02%465K | 19.15%2.91M | 137.43%1.2M |
| Non-operating interest income | -36.62%559K | 25.28%13.21M | -10.46%882K | 109.22%10.55M | 229.94%5.94M | 69.04%1.59M | 67.82%2.03M | -9.55%985K | 15.09%5.04M | 75.95%1.8M |
| Non-operating interest expense | 32.78%806K | 10.95%2.16M | 16.73%607K | -8.64%1.95M | -17.97%493K | 29.60%451K | -31.58%481K | 9.01%520K | 9.97%2.13M | 16.02%601K |
| Net investment income | 19.88%16.15M | -22.82%33.98M | -53.43%13.47M | -60.25%44.03M | -183.80%-6.08M | -92.84%6.61M | 184.18%14.58M | 1.43%28.92M | 54.75%110.76M | -78.31%7.25M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 0 | -9.00%50.68M | 0 | 0 | 55.69M | 0 | ||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 99.98%-23K | -242.94%-195.88M | -928.90%-104.58M | 90.21%-57.12M | 85.83%-49.19M | -37.75%18.57M | 78.63%-16.34M | 94.64%-10.16M | -1,339.29%-583.43M | -2,689.53%-347.27M |
| Less:Other special charges | -99.98%23K | 242.94%195.88M | 928.90%104.58M | -76.19%57.12M | 1,210.71%49.19M | 37.75%-18.57M | -78.63%16.34M | -94.64%10.16M | 491.85%239.91M | -69.85%3.75M |
| Less:Write off | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --343.52M | ---- |
| Other non-operating income (expenses) | -16.66%8.13M | 629.45%17.29M | -38.43%9.75M | 92.80%-3.27M | 172.55%10.85M | 29.41%-31.05M | -84.34%1.1M | 141.62%15.84M | -237.22%-45.39M | -222.95%-14.96M |
| Income before tax | 39.91%853.65M | 10.88%3.9B | -36.99%610.13M | 47.51%3.52B | 49.64%809.67M | 0.16%977.51M | 29.02%762.32M | 249.67%968.32M | -24.81%2.38B | -43.97%541.08M |
| Income tax | 23.53%258.52M | 20.25%1.04B | -26.47%209.29M | 47.88%865.44M | 395.47%159.65M | -19.74%233.29M | 8.72%187.89M | 217.91%284.61M | -37.88%585.24M | -88.21%32.22M |
| Net income | 48.47%595.13M | 7.82%2.86B | -41.37%400.84M | 47.39%2.65B | 27.74%650.02M | 8.60%744.22M | 37.41%574.43M | 264.83%683.72M | -19.28%1.8B | -26.51%508.86M |
| Net income continuous operations | 48.47%595.13M | 7.82%2.86B | -41.37%400.84M | 47.39%2.65B | 27.74%650.02M | 8.60%744.22M | 37.41%574.43M | 264.83%683.72M | -19.28%1.8B | -26.51%508.86M |
| Noncontrolling interests | 0 | |||||||||
| Net income attributable to the company | 48.47%595.13M | 7.82%2.86B | -41.37%400.84M | 47.39%2.65B | 27.74%650.02M | 8.60%744.22M | 37.41%574.43M | 264.83%683.72M | -19.28%1.8B | -26.51%508.86M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 48.47%595.13M | 7.82%2.86B | -41.37%400.84M | 47.39%2.65B | 27.74%650.02M | 8.60%744.22M | 37.41%574.43M | 264.83%683.72M | -19.28%1.8B | -26.51%508.86M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 48.37%48.31 | 7.74%232.19 | -41.42%32.5608 | 47.28%215.51 | 27.63%52.8 | 8.51%60.46 | 37.31%46.67 | 264.46%55.58 | -19.34%146.33 | -26.57%41.37 |
| Diluted earnings per share | 48.37%48.31 | 7.74%232.19 | -41.42%32.5608 | 47.28%215.51 | 27.64%52.8 | 8.52%60.4538 | 37.31%46.6614 | 264.46%55.58 | -19.34%146.33 | -26.57%41.3651 |
| Dividend per share | 0 | 30.00%65 | 0 | 11.11%50 | 22.73%27 | 0 | 0.00%23 | 0 | 0.00%45 | -4.35%22 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |